The Week in Review: SFDA Drug Approvals Drop in 2011

Published: Oct 16, 2012

by Richard Daverman, PhD

October 13, 2012 -- In 2011, the SFDA issued fewer drug approvals and allowed a smaller number of clinical trials in China than the year earlier, but the agency received a larger number of applications for drug registration; LoneStar Heart of California raised up to $20 million from a Hong Kong PE fund to develop its medical device for heart failure; Fosun Pharma’s $600 million Hong Kong IPO is being marketed as a value play given that its Sinopharm holding equals 80% of the company's market capitalization; TranS1 Inc. of the US has struck a distribution deal with Beijing Jiade Sunshine for its spinal implants in mainland China; Cephasonics, a Silicon Valley maker of ultrasound components, signed a China distribution agreement with Excelpoint Systems of Hong Kong; and Tianyin Pharma reported that its new $25 million production facility is on track for completion early next year. More details….

Stock Symbols: (SHA: 600196) (HK: 1096) (NSDQ: TSON) (AMEX: TPI)

Back to news